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Background: The CYP2D6 gene locus has been extensively studied over decades, yet a
portion of variability in CYP2D6 activity cannot be explained by known sequence variations
within the gene, copy number variation, or structural rearrangements. It was proposed
that rs5758550, located 116 kb downstream of the CYP2D6 gene locus, increases gene
expression and thus contributes to variability in CYP2D6 activity. This ﬁnding has,
however, not been validated. The purpose of the study was to address a major
technological barrier, i.e., experimentally linking rs5758550, also referred to as the
“enhancer” single-nucleotide polymorphism (SNP), to CYP2D6 haplotypes >100 kb
away. To overcome this challenge is essential to ultimately determine the contribution
of the “enhancer” SNP to interindividual variability in CYP2D6 activity.
Methods: A large ethnically mixed population sample (n=3,162) was computationally
phased to determine linkage between the “enhancer” SNP and CYP2D6 haplotypes (or
star alleles). To experimentally validate predicted linkages, DropPhase2D6, a digital
droplet PCR (ddPCR)-based method was developed. 10X Genomics Linked-Reads
were utilized as a proof of concept.
Results: Phasing predicted that the “enhancer” SNP can occur on numerous CYP2D6
haplotypes including CYP2D6*1, *2, *5, and *41 and suggested that linkage is incomplete,
i.e., a portion of these alleles do not have the “enhancer” SNP. Phasing also revealed
differences among the European and African ancestry data sets regarding the proportion
of alleles with and without the “enhancer” SNP. DropPhase2D6 was utilized to conﬁrm or
refute the predicted “enhancer” SNP location for individual samples, e.g., of n=3 samples
genotyped as *1/*41, rs5758550 was on the *41 allele of two samples and on the *1 allele
of one sample. Our ﬁndings highlight that the location of the “enhancer” SNP must not be
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assigned by “default.” Furthermore, linkage between the “enhancer” SNP and CYP2D6
star allele haplotypes was conﬁrmed with 10X Genomics technology.
Conclusions: Since the “enhancer” SNP can be present on a portion of normal,
decreased, or no function alleles, the phase of the “enhancer” SNP must be
considered when investigating the impact of the “enhancer” SNP on CYP2D6 activity.
Keywords: CYP2D6, allele deﬁnition, enhancer SNP, ddPCR = droplet digital PCR, phasing

rs5758550 into pharmacogenetic test panels, but also suggested
that testing of rs5758550 may be more informative than testing
SNPs that identify particular star alleles (Wang et al., 2014; Wang
et al., 2015; Ray et al., 2019). There are, however, no additional
published studies to date corroborating the impact of the
“enhancer” SNP on CYP2D6 activity in-vivo demonstrating
that combined genotyping for rs5758550 and rs16947 is
superior over the current methods focusing on SNPs that
identify star alleles of interest. Moreover, the “enhancer” SNP
does not appear to be in complete linkage disequilibrium with
rs16947, and rs16947 is not only part of the CP2D6*2 core allele
deﬁnition (Gaedigk et al., 2019a), but also found on numerous
other allelic variants (Figure 1). There are also considerable
differences in the frequency of the “enhancer” SNP among
populations, suggesting that this SNP may occur on many
CYP2D6 haplotypes.
The “enhancer” SNP (rs5758550) is listed by dbSNP as G>A
with “G” being the minor allele with a global frequency of 28%
per the gnomAD database. Wang et al. ascribed increased
activity to the presence of “G” and hence referred to this
nucleotide as the SNP of primary interest in their publications.
Throughout this report, we refer to “G” (the “enhancer” SNP) as
the variant allele and “A” as the reference allele, consistent with
the dbSNP database as well as our own observations that the vast
majority of CYP2D6*1 alleles have “A” at this position.
The long physical distance between the CYP2D6 gene locus
and rs5758550 poses a challenge to unequivocally determining
the phase of CYP2D6 gene locus SNPs and the “enhancer” SNP,
unless both alleles carry the rs5758550 SNP. While statistical
inference of linkage can be predicted by bioinformatics tools,
experimental validation remains the gold standard. Methods
often utilized to establish SNP linkage such as allele-speciﬁc
long-range PCR or single molecule sequencing either do not
allow ampliﬁcation over 20 kb or are costly and labor-intensive.
In droplet digital PCR (ddPCR), a reaction is divided into up
to 20,000 nanoliter-sized droplets, enabling PCR ampliﬁcation
from a single DNA molecule; this technology, combined with
allele-speciﬁc TaqMan® probes, can rapidly phase two SNP loci
that are thousands of bases apart (Roberts et al., 2014; KarlinNeumann and Bizouarn, 2018; Lunenburg et al., 2018; Tsujimoto
et al., 2018). This method is a robust and scalable molecular
phasing approach that allowed Regan et al. to perform haplotype
analysis of loci up to 200 kb apart (Regan et al., 2015).
This investigation aimed to address a number of questions that
arose from the work published by Wang and colleagues including:
what is the proportion of CYP2D6*2 alleles with and without the

INTRODUCTION
The highly polymorphic CYP2D6 gene encodes the cytochrome
P450 2D6 enzyme, which contributes to the metabolism and
bioactivation of numerous clinically used drugs (Zhou, 2009a;
Zhou, 2009b; Saravanakumar et al., 2019). The Clinical
Pharmacogenomics Consortium (CPIC) has published
guidelines for a number of CYP2D6 gene-drug pairs (Crews
et al., 2014; Hicks et al., 2015; Hicks et al., 2016; Bell et al., 2017;
Goetz et al., 2018; Brown et al., 2019) substantiating the
important role of CYP2D6-mediated drug metabolism. The
Pharmacogene Variation Consortium (PharmVar) (Gaedigk
et al., 2018b) currently deﬁnes >130 allelic variants for
CYP2D6, which are the most important factors explaining
variability in CYP2D6 activity (Hicks et al., 2013). While
CYP2D6 activity is well predicted by genetic variation within
the gene locus (i.e., exons and introns), there is still substantial
variability among individuals with the same genotype that
remains unexplained.
CYP2D6 activity varies widely among individuals and
populations (Gaedigk et al., 2017). A large portion of the
observed variability can be explained by known genetic
variation within the CYP2D6 gene locus (Gaedigk et al., 2008;
Gaedigk et al., 2018a; Ning et al., 2018; Dalton et al., 2019).
Searching for additional loci beyond the immediate CYP2D6
gene region, Wang et al. (2015) described that rs5758550, located
116 kb downstream of exon 9 of the CYP2D6 gene' is associated
with CYP2D6 activity. This single nucleotide polymorphism
(SNP) has been proposed to impact CYP2D6 activity by
modulating expression levels, and thus may account for
unexplained variability, especially within a given diplotype
(Wang et al., 2014; Wang et al., 2015). Wang et al. reported
that rs5758550 “G” was associated with a two-fold increase of
messenger RNA (mRNA) transcription levels (Wang et al.,
2015). In a follow-up report the same group showed that
2851C>T (rs16947), which is part of the “normal function”
CYP2D6*2 haplotype, was associated with a two-fold reduction
in expression levels by causing alternative splicing of intron 6
(Wang et al., 2014). Taken together, the authors suggested that
the presence or absence of rs5758550, which is also referred to as
the CYP2D6 “enhancer” SNP, in combination with rs16947, is a
better predictor of CYP2D6 activity compared to the traditional
and widely-accepted approach of using star allele-based
diplotypes (or genotypes—the terms are often used
interchangeably) (Wang et al., 2015; Ray et al., 2019). Based on
their ﬁndings, the authors not only proposed to include
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FIGURE 1 | Graphical overview of CYP2D6 alleles relevant to this study. Gray boxes represent the nine exons and lines represent intervening sequences as well as
upstream and downstream regions. Each allele is displayed with its core single-nucleotide polymorphism(s) [SNP(s)], i.e., SNPs that either cause an amino acid
change or impact splicing. SNPs are represented using their respective rs IDs. The SNP shown with a blue line (rs16947, g.2851C>T) highlights the CYP2D6*2 core
SNP which is also part of the CYP2D6*14, *17, *21, *29, *35, *41, *45, *46 and *59 core allele deﬁnitions. The SNP shown with a green line (rs1135840,
g.4181G>C) is also part of many core allele deﬁnitions. SNPs highlighted by a red line denote core SNPs rs numbers in brackets occur in some but not all alleles. In
addition, the graph also shows rs1080985 (g.-1584C>G), a SNP that is most often found on CYP2D6*2 (formerly known as *2A), but has also been shown to be
part of other haplotypes including CYP2D6*14, *21, *35 and *59; it is displayed in brackets if it is not present on all known suballeles. Lastly, rs5758550 denotes the
“enhancer” SNP, which is shown in brackets if it does not occur on all suballeles based on the ﬁndings of this study. We refer to pharmvar.org/gene/CYP2D6 for a
complete list of all SNPs found on a star allele.
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“enhancer” SNP? Do other haplotypes containing rs16947 also
have the “enhancer” SNP—all or just some? Are there populationspeciﬁc differences? In other words, to further investigate the
impact of the “enhancer” SNP on CYP2D6 activity, it is essential
to know which haplotypes (star alleles) can carry this SNP and
experimentally establish on which allele the “enhancer” SNP is
located in heterozygous samples. To provide this crucial
information, we 1) computationally phased a large dataset of
>3,000 ethnically diverse samples in order to determine which
CYP2D6 star alleles carry the “enhancer” SNP, and 2) established a
ddPCR-based assay, referred to as the DropPhase2D6 assay, that
can experimentally conﬁrm linkage of computationally predicted
haplotypes. While this investigation focuses on CYP2D6, it can
easily be adapted to other genetic loci.

RefSeq NG_008376.3 with the ATG start codon being +1 according
to PharmVar at https://www.pharmvar.org/gene/CYP2D6.

Computational Phasing
Haplotypes were constructed from samples (n=3162) (Table 2)
using PHASE (v2.1.1) (Stephens et al., 2001). Fifteen commonly
genotyped SNPs were chosen for phasing analysis
(Supplemental Table 1). An artiﬁcial “SNP” (GRCh37
chr22:42528383) was assigned as a surrogate for the CYP2D6*5
gene deletion. The majority of samples had results for all 15 SNPs
and the gene deletion. Samples known to contain rare alleles
(e.g., *7, *11, *21, *59, etc.) were excluded from the
computational data analysis. Ethnicity was available for
n=2,564 samples. Phasing was performed for all samples
(n=3162), regardless of ethnicity (dataset_all). Separate
population-speciﬁc analyses were performed for samples with
African (n=603) and European (n=1474) ancestries (dataset_A
and dataset_E).

METHODS
Study Samples
Sample and genotype data were compiled from previous studies
(Abduljalil et al., 2010; Gaedigk et al., 2012; Montane Jaime et al.,
2013; Tay-Sontheimer et al., 2014; Brown et al., 2016; Bérard
et al., 2017; Gaedigk et al., 2019b) as well as ongoing studies
(Genomic- and Ontogeny-Linked Dose Individualization and
cLinical Optimization for Kids (GOLDILOKs), CYP2D6
genotype and neurocognitive dysfunction in methamphetamine
users with and without HIV and medication use in pregnant
women). Studies into which participants were initially enrolled
in were approved by the institutions at which the studies were
performed. Written informed consent to participate in a study
was provided by participants. The use of repository samples and
human liver tissue samples was approved by the Children's
Mercy Hospital internal review board. DNA was sourced from
either whole blood, saliva, or liver tissue. The panel also included
samples obtained from the Coriell Institute for Medical Research
(www.coriell.org) (n=254), a PGx repository maintained at
Children's Mercy (n=115), and liver tissue samples obtained
from the Liver Tissue Cell Distribution System (n=150), the
National Institute of Child Health and Human Development
(NICHD)–supported tissue retrieval program at the University
of Maryland Brain and Tissue Bank for Developmental
Disorders (Baltimore, MD) (n=103) and Sekisui XenoTech
LLC (n=28). Ethnicities were self-reported.

DNA Preparation
Long-distance phasing by ddPCR requires high molecular weight
(HMW) DNA samples. To assess the suitability of DNA for
DropPhase2D6, different commercially available kits were
evaluated. To limit shearing, all pipetting steps (including
handling of blood and DNA) were carried out with 200 µl
BioClean Ultra™ Wide-O LR Filter Sterilized pipette tips
(Rainin, Oakland, CA) and 10 µl BioClean Ultra™ Filter tips
cut with a scalpel to create a wide bore tip. Ethylenediaminetetraacetic acid (EDTA) whole blood samples were
processed and frozen at −80°C within 24 hrs of collection.
White blood cells were isolated from blood, resuspended in 1x
phosphate-buffered saline (2.7 mM KCl, 10 mM KH2PO4, 137
mM NaCl, 1.8 mM anhydrous Na2HPO4, pH 7.4) in 20% of the
original blood volume, and immediately used for DNA
extraction or frozen at −80°C.
DNA quality was assessed by 0.5% agarose gel electrophoresis
and the concentration determined using a NanoDrop One
instrument (Thermo Fisher Scientiﬁc, Waltham, MA).

DNeasy Blood and Tissue Kit (Qiagen, Hilden,
Germany)
To serve as a comparison to HMW DNA preparations, DNA was
isolated with this silica column-based DNA extraction kit. Blood
and tissue samples were prepared as per manufacturer's protocol.

Genotyping
Genomic DNA was prepared from whole blood or liver tissue and
genotyped for a minimum of four SNPs (rs5758550 or rs133333,
rs16947, rs3892097, and rs1065852) as previously described
(Gaedigk et al., 1999; Gaedigk et al., 2006; Gaedigk et al., 2007;
Gaedigk et al., 2008; Gaedigk et al., 2010a; Gaedigk et al., 2010b;
Gaedigk et al., 2012; Gaedigk et al., 2015; Gaedigk et al., 2019b) and
detailed in Supplemental Table 1. This format for methods
reporting has been recommended by PharmVar and PharmGKB
to facilitate standardized genotype method reporting (Nofziger
et al., 2020). All SNP positions are in reference to the CYP2D6
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PrepFiler™ Forensic DNA Extraction Kit (Applied
Biosystems, Foster City, CA)
DNA was extracted from whole blood or white blood cells with
the PrepFiler Forensic DNA Extraction Kit as described by
Regan et al. (2015) with the following modiﬁcations: 200 µl of
frozen whole blood or 40 µl of white blood cell suspension were
used in lieu of cultured cells. The elution step was repeated 3x, as
subsequent elutions from the beads yielded increasing quality of
HMW DNA.
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MagAttract® HMW DNA Kit (Qiagen, Hilden,
Germany)

rs16947varT and rs5758550varG assays were used. We will refer
to the combination of the two custom TaqMan® SNP assays as a
“duplex.” DropPhase2D6 was carried out as follows: 1) the two
selected 40x assay mixes were combined with ddPCR Supermix
for Probes without dUTP (Bio-Rad, Hercules, CA) and added to
each well; 2) 10–30 ng HMW DNA was added; 3) H2O was
added for a total volume of 22 µl, and 4) the reaction was gently
mixed by pipetting 15 times with a Rainin wide-oriﬁce P200 tip;
5) the 96 well plate was gently vortexed at low speed for three
pulses and spun for 2 min at 2,000xg. After generating droplets
using the Auto Droplet Generator (Bio-Rad, Hercules, CA), the
plates were heat-sealed with a foil cover (Bio-Rad) and cycled in a
C1000 Touch Thermocycler (Bio-Rad). The thermal cycling
protocol was as follows: 10 min at 95°C for 1 cycle, 40 cycles
of 30 s at 94°C and 1 min at 60°C, and a ﬁnal cycle of 98°C for 10
min. Droplets were read on the QX-200 Droplet Digital PCR
system (Bio-Rad) and linkage analysis was performed with the
QuantaSoft™ Analysis Pro software v.1.0.596. Linkage is
expressed as a percent of all molecules that are linked as
described in Regan et al. (2015).
Two control strategies were utilized for the DropPhase2D6
experiment. First, 150 ng of HMW DNA was digested with 10 U
of EcoRI-HF restriction enzyme (RE) (New England Biolabs,
Ipswich, MA) at 37°C for 1.5 h followed by RE inactivation at 65°
C for 20 min. Digested DNA was subsequently used in place of
HMW DNA as a no-linkage control. The second strategy
included testing all possible allelic conﬁgurations of a
compound heterozygote. This is achieved by performing two
duplex reactions. One duplex reaction is expected to be in linkage
(interrogated SNPs are in cis) while the other duplex reaction is
expected not to show linkage (interrogated SNPs are in trans).
For example, in a sample genotyped as CYP2D6*1/*2
(heterozygous for rs16947 and rs5758550), linkage between the
interrogated SNPs is observed when using the rs16947varT
+rs5758550varG duplex reaction, while the rs16947refC
+rs5758550varG duplex reaction results in no linkage. If
linkage cannot be established with one of the duplex reactions,
DNA quality is likely insufﬁcient.
To determine linkage, we adopted a conservative cut-off value
of 5% linked molecules, i.e., linkage must be greater than 5% for
SNPs over 100 kb apart to be called as linked. Additionally, the

DNA was extracted from whole blood, white blood cell
suspensions or 25 mg of frozen liver tissue per manufacturer's
protocol with the following modiﬁcations: 50 µl of suspended
white blood cells or 50 µl of whole blood was used instead of 200
µl whole blood and the tubes were gently ﬂicked instead of
shaken at 1,400 rpm.

MegaLong™ DNA Extraction Kit (G-Biosciences, St.
Louis, MO)
DNA was extracted from whole blood, white blood cell
suspension or 25 mg of frozen liver tissue per manufacturer's
protocol with the following modiﬁcations: 100 µl of frozen whole
blood or 15 µl of white blood cell suspension was substituted for
fresh whole blood. Cell suspensions were centrifuged at 16,000xg
for 10 min, instead of 5 min, to pellet the cells and then washed
with 100 µl of the nuclei isolation buffer after removing the
supernatant. This additional wash step facilitated the removal of
excess lysis debris.

Experimental Phasing Using ddPCR—
DropPhase2D6
Probe and Assay Design
TaqMan® SNP assays were custom ordered from Life
Technologies (Carlsbad, CA, USA). Each 40x assay consisted
of two probes, one with a ﬂuorophore and quencher while the
other had only a non-ﬂorescent quencher (NFQ), referred to in
this report as a “dark probe.” For 2851C>T (rs16947), two 40x
assays were designed, i.e., T-FAM+C-dark and C-FAM+T-dark,
allowing us to detect signal for either the “C” or “T” allele. For all
other assays, VIC labeled probes were used. Another probe set
for the CYP2D6*4 core SNP (1847G>A) was validated after the
method was established for 2851C>T. DropPhase2D6 assay
names, their TaqMan® assay IDs, and the SNP-speciﬁc probes
labeled with ﬂuorophores are shown in Table 1.

Linkage Duplex Assays
For each linkage reaction, two 40x assays were combined: an
rs16947-FAM assay with a VIC-containing assay. For example,
to evaluate linkage between rs16947 “T” and rs5758550 “G,” the

TABLE 1 | Custom Dark Probe TaqMan® assays for DropPhase2D6.
TaqMan® assay
ID
C__27102425_10
C__27102425_10
C__27102431_D0
C__61226317_10
C__30485108_10
C__29692254_10
C__29692254_10

DropPhase2D6
assay name

Custom ID

rs number

SNP
location

Dye

Fluorophore
on

NFQ
on

rs16947varT
rs16947refC
rs3892097varT
rs28817600varG
rs5758562varC
rs5758550varG
rs5758550refA

C__27102425_10AF
C__27102425_10GF
C__27102431_D0TF
C__61226317_10GV
C__30485108_10CV
C__29692254_10GV
C__29692254_10AV

rs16947
rs16947
rs3892097
rs28817600
rs5758562
rs5758550
rs5758550

exon 6
exon 6
intron 3
25 kb
75 kb
116 kb
116 kb

FAM
FAM
FAM
VIC
VIC
VIC
VIC

A
G
C
G
C
G
A

G
A
T
A
G
A
G

TaqMan® Assay ID and Custom Assay ID refer to the original TaqMan® assays and their corresponding customized assay. The ﬂuorescent dye (FAM and VIC) are as speciﬁed. For
example, C__27102425_10AF is a modiﬁed C__27102425_10 assay allowing interrogation of rs16947 “A” with FAM. In the text we refer to the assays by their DropPhase2D6 assay
name, which includes the SNP rs number and the allele of interest (generating a ﬂuorescent signal). The SNP location indicates the location of rs16947 and rs3892097 within the CYP2D6
gene and the approximate downstream positions of SNPs interrogated for linkage with rs16947. NFQ, non-ﬂuorescent quencher (or dark probe). Note that dbSNP reports rs5758562C>G
(MAF=0.27) while we refer to “G” as reference and “C” as the variant.
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SNP. For example, while almost all CYP2D6*2 in the European
subset were predicted to carry rs5758550 “G” (95.8%), only
71.3% of samples with African ancestry were predicted to carry
it (Table 2). Phasing also suggested that a substantial proportion
of CYP2D6*1 alleles carry the “enhancer” SNP (0.7 and 29.2%,
respectively, when European and African ancestry samples were
phased separately), a ﬁnding that needs to be viewed with
caution. For example, since CYP2D6*1 is a default assignment
(e.g., *15, *22–*27, *33, *39, *43 and others were not
discriminated by genotyping and therefore were designated *1
by “default”) the number of true *1 alleles carrying the
“enhancer” SNP may be lower. Similarly, CYP2D6*11, *12,
*19–*21, *59, and numerous other haplotypes were defaulted to
a CYP2D6*2 assignment which likely contributed to an overestimation of true *2 alleles carrying the “enhancer” SNP.
Another SNP of interest was −1584C>G (rs1080985) which in
the past has been implicated to play a regulatory role for
CYP2D6 function (Raimundo et al., 2000; Raimundo et al.,
2004). This SNP is predominantly, but not exclusively, found
on CYP2D6*2 alleles. As shown in Table 2, rs1080985
(−1584C>G) and rs5758550 (“enhancer” SNP) are in linkage
disequilibrium, i.e., the majority of CYP2D6*1 alleles do not have
either SNP, while the majority of CYP2D6*2 alleles possess both.
This table provides predicted frequencies stratiﬁed by allele and
the presence of −1584C>G (rs1080985) and/or rs5758550
(“enhancer” SNP). For example, within dataset_E (Europeans)
509 alleles were called CYP2D6*2 by the PHASE algorithm of
which four (0.7%) were predicted to not have −1584C>G or the
“enhancer” SNP, 17 (3.3%) were predicted to have −1584C>G, 11
(2.1%) were predicted to have the “enhancer” SNP, and 477
(93.7%) were predicted to have both SNPs. It follows that the
cumulative predicted frequency of CYP2D6*2 alleles with the
“enhancer” SNP is 95.8%.
For other ethnic groups it was also observed that the majority of
CYP2D6*2 alleles carry the “enhancer” SNP as well as the SNP at
position -1584. Hispanics (n=176 subjects), East Asians (n=98
subjects), and subjects of Indian ancestry (n=210), 69/352, 26/196,
and 77/410 alleles were phased as CYP2D6*2 with 62 (90%), 18
(69%), and 74 (96%), respectively and predicted to carry both SNPs.
In African Americans, however, only 42% of CYP2D6*2 alleles are
computationally predicted to have the “enhancer” SNP as well as
−1584C>G. Differences were also observed for other alleles between
these populations and our larger European and African-ancestry
cohorts (not shown). These predictions are, however, estimates due
to the small numbers of alleles observed with or without the
“enhancer” SNP and HMW DNA was not available for
experimental conﬁrmation.

difference between the positive and negative control duplex
reactions must have at least a 5% linked molecules difference.
For example, interrogated SNPs are determined to be linked, if
the rs16947varT+rs5758550varG duplex reaction yields e.g., 10%
linked molecules and the rs16947refC+rs5758550varG duplex
reaction yields 0.3% linked molecules and thus differ by >5%
between the two reactions. The SNPs are not called linked if the
duplex reaction yields e.g., 4.5% linked molecules and the
rs16947refC+rs5758550varG duplex reaction yields 0.5%
linked molecules.
Assay conditions linking the “enhancer” SNP with 1847G>A
were identical to those described for 2851C>T.

Long Distance Phasing With 10x Genomics
The 10X Genomics Linked-Reads platform allows phasing of
sequence variations across >10 Mb haplotype blocks (https://
www.10xgenomics.com). Publicly available 10X Genomics
Linked-Read data from the Illumina HiSeqX-PGx Cohort were
used as proof-of-concept for phasing the “enhancer” SNP with
CYP2D6 haplotypes, i.e., selected star allele-identifying core
SNPs. Data were obtained at https://github.com/Illumina/
Polaris/wiki/HiSeqX-PGx-Cohort and analyzed with Long
Ranger v2.2.2 and Loupe software v2.1 (10XGenomics,
Pleasanton, CA) against the GRCh37 reference genome.

RESULTS
Computational Phasing
In order to determine which CYP2D6 haplotypes (or star alleles)
carry the “enhancer” SNP, a dataset comprising genotype
information from 3,162 samples (based on 15 SNPs and a
surrogate “SNP” representing the CYP2D6*5 gene deletion)
was subjected to computational haplotype phasing. Phasing
was performed on all samples (dataset_all) and by ethnicity/
race (n=1482), European (White, Caucasian; dataset_E), and
n=609, African (Black, Africa, African American; dataset_A).
Haplotype predictions and frequencies for all three datasets are
summarized in Table 2. As shown in this table, predictions
varied considerably for CYP2D6*5, *29, and *41 haplotypes,
depending on whether phasing was performed on the entire
multiethnic cohort or within their racial/ethnic group. For
example, separately phasing the European and African datasets
suggested that only one of the alleles phased as CYP2D6*29 has
the “enhancer” SNP. In contrast, when phasing was done on the
entire cohort, 16 alleles were predicted to have the “enhancer”
SNP on a CYP2D6*29 allele. However, as described below,
experimental phasing with DropPhase2D6 ultimately
demonstrated that the “enhancer” SNP was not located on the
CYP2D6*29 allele in this sample.
Phasing revealed that the “enhancer” SNP is most often found
on haplotypes carrying the CYP2D6*2 core SNP (2851C>T,
rs16947) including CYP2D6*2, *17, and *35 among others
(Figure 1; for core allele deﬁnitions see Gaedigk et al., 2019a;
Nofziger et al., 2020). However, regardless of ethnicity, star allele
haplotypes were not in complete linkage with the “enhancer”
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DropPhase2D6 Assay Validation
To establish DropPhase2D6, assays were tested using six Coriell
DNA samples with known genotypes for rs5758550 (“enhancer”
SNP) and rs16947 (Figure 2): NA19663, HG00650 (homozygous
reference), HG00594, NA12248 (compound heterozygote), and
HG00275, NA20360 (homozygous variant).
When interrogating NA20360 (homozygous variant), using
the rs16947varT+rs5758550varG duplex reaction (Table 1),
FAM as well as VIC signals were detected. Analysis with
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TABLE 2 | Computational haplotype determination using PHASE.
Star
allele

Allele carries

Haplotype frequency
dataset_all n=6,324

Haplotype frequency
dataset_E n=2,964

Haplotype frequency
dataset_A n=1,218

All samples phased together; n=number of alleles

Haplotype frequency
dataset_E n=2,964

Haplotype frequency
dataset_A n=1,218

Phased E only

Phased A only

n= Number of allele (% of given allele)
*1

none
rs5758550
rs1080985
rs5758550
rs1080985

(enhancer SNP)
(−1584C>G)+
(enhancer SNP)
(−1584C>G)

2,236 (94.6%)
121 (5.1%)
3 (0.1%)

1,104 (98.6%)
12 (1%)
2 (0.1%)

304 (76.9%)
91 (23%)
0 (0%)

1,110 (99.1%)
6 (0.5%)
3 (0.2%)

280 (70.7%)
116 (29.2%)
0 (0%)

2 (0%)

1 (0%)

0 (0%)

0 (0%)

0 (0%)

*10

none
rs5758550 (enhancer SNP)
rs5030655 (*6)

248 (98.8%)
3 (1.1%)
0 (0%)

48 (97.9%)
1 (2%)
0 (0%)

43 (97.7%)
1 (2.2%)
0 (0%)

48 (97.9%)
1 (2%)
0 (0%)

42 (95.4%)
1 (2.2%)
1 (2.2%)

*17

none
rs5758550 (enhancer SNP)

4 (1.6%)
236 (98.3%)

0 (0%)
13 (100%)

3 (1.5%)
194 (98.4%)

0 (0%)
13 (100%)

5 (2.5%)
192 (97.4%)

*2

none
rs1080985
rs5758550
rs1080985
rs5758550

66 (6%)
33 (3%)
94 (8.6%)
898 (82.3%)

3 (0.5%)
18 (3.5%)
11 (2.1%)
476 (93.7%)

60 (27.6%)
2 (0.9%)
65 (29.9%)
90 (41.4%)

4 (0.7%)
17 (3.3%)
11 (2.1%)
477 (93.7%)

63 (28.6%)
0 (0%)
65 (29.5%)
92 (41.8%)

113 (87.5%)
15 (11.6%)
1 (0.7%)

3 (100%)
0 (0%)
0 (0%)

94 (87%)
14 (12.9%)
0 (0%)

2 (100%)
0 (0%)
0 (0%)

106 (99%)
1 (0.9%)
0 (0%)

(−1584C>G)
(enhancer SNP)
(−1584C>G)+
(enhancer SNP)

*29

none
rs5758550 (enhancer SNP)
rs1080985 (−1584C>G)+
rs5758550 (enhancer SNP)

*3

none

66 (100%)

48 (100%)

4 (100%)

48 (100%)

4 (100%)

*35

rs1080985 (−1584C>G)
rs1080985 (−1584C>G)+
rs5758550 (enhancer SNP)

7 (2.9%)
229 (97%)

7 (4.3%)
154 (95.6%)

0 (0%)
4 (100%)

9 (5.5%)
152 (94.4%)

0 (0%)
4 (100%)

*4

none
rs5758550 (enhancer SNP)

974 (99.2%)
1 (0.1%)

561 (99.1%)
1 (0.1%)

95 (100%)
0 (0%)

561 (99.1%)
1 (0.1%)

95 (100%)
0 (0%)

*4.012 none

6 (0.6%)

4 (0.7%)

0 (0%)

4 (0.7%)

0 (0%)

12 (100%)

0 (0%)

10 (100%)

0 (0%)

10 (100%)

none
rs5758550 (enhancer SNP)
rs1080985 (−1584C>G)+
rs5758550 (enhancer SNP)

489 (97.9%)
9 (1.8%)
1 (0.2%)

282 (97.9%)
5 (1.7%)
1 (0.3%)

32 (94.1%)
2 (5.8%)
0 (0%)

276 (95.8%)
11 (3.8%)
1 (0.3%)

30 (96.7%)
1 (3.2%)
0 (0%)

*45

none
rs5758550 (enhancer SNP)

56 (98.2%)
1 (1.7%)

1 (100%)
0 (0%)

41 (97.6%)
1 (2.3%)

1 (100%)
0 (0%)

41 (97.6%)
1 (2.3%)

*5
*6

none
rs5758550 (enhancer SNP)
none

199 (85%)
35 (14.9%)
39 (100%)

88 (90.7%)
9 (9.2%)
32 (100%)

45 (72.5%)
17 (27.4%)
1 (100%)

88 (90.7%)
9 (9.2%)
32 (100%)

56 (90.3%)
6 (9.6%)
1 (100%)

*69

none

1 (100%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

*9

none

126 (100%)

79 (100%)

5 (100%)

79 (100%)

5 (100%)

*40

none

*41

Phasing was performed using dataset_all (all samples, n=3,162) and frequencies for samples with European and African ancestry calculated after phasing was performed. Phasing for
dataset_E (samples with European ancestry, n=1,482) and dataset_A (samples with African ancestry, n=609) was performed on each dataset separately. Frequency denotes the
frequency of the haplotype per PHASE output. The left-hand column provides the core star allele designation to which a haplotype matches. *4.012 denotes a *4 suballele lacking 100C>T,
a SNP that is present in all other deﬁned *4 suballeles. Of note, dbSNP reports rs1080985 as G>C (gnomAD MAF=0.2) while we refer to “C” as reference and “G” as variant. none denotes
that allele does not have rs5758550 ("enhancer" SNP) or rs1080985 (-1584C>G).

into the same droplet by chance, and the cluster with no signals
(gray) representing droplets that do not contain DNA with either
of the interrogated SNPs. Note that cluster density is inversely
correlated with DNA integrity, i.e., the intensity of the blue and
green clusters is lower for samples with higher integrity DNA
compared to samples with lower-integrity DNA. We also
observed a lower signal height of the double-positive FAM and
VIC cluster (orange) compared to the single positive FAM (blue)
or VIC (green) clusters which we attributed to decreased PCR

QuantaSoft software displayed four different clusters, shown in
Figure 2A: the single ﬂuorophore-positive clusters (blue and
green) represent signals produced from droplets containing
DNA fragments harboring one of the two interrogated SNPs
(DNA breaks may have occurred between the two SNPs
“unlinking” signals into discrete clusters); a cluster that is
positive for both ﬂuorophores (orange), representing droplets
containing DNA fragments carrying both SNPs or, in rare cases,
multiple (often smaller) DNA fragments that were partitioned
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A

NA20360
FAM Fluorscence

116 kb

T

FAM

VIC

G

VIC

CYP2D6

*2

T

FAM

CYP2D6

*2

rs16947 C>T

B

G

rs5758550 A>G

FAM Fluorscence

HG00594
T

FAM

*2

CYP2D6

*1

CYP2D6

C

Dark

rs16947 C>T

C

VIC

G

A Dark

rs5758550 A>G

FAM Fluorscence

NA19663
C

Dark

A Dark

CYP2D6

*10

C

Dark

A Dark

CYP2D6

*10

rs16947 C>T

rs5758550 A>G

VIC Fluorscence
FIGURE 2 | DropPhase2D6 assay development. Assays designed for DropPhase2D6 were evaluated using Coriell DNA samples with known genotypes. (A)
NA20360 is homozygous variant for the two single-nucleotide polymorphisms (SNPs) of interest yielding three distinct clusters: green, VIC [droplets containing
genomic DNA (gDNA) with rs5758550G)], blue FAM (droplets containing gDNA with rs16947T), and orange, denoting a double-positive cluster (droplets containing
DNA molecules generating FAM and VIC signal). (B) HG00594 is heterozygous for both SNPs displaying the same cluster pattern as shown in (A). The observed
“rain” on the scatter plot is a commonly observed feature believed to be due to probe competition for PCR reaction components. (C) NA19663 is homozygous
reference for both loci, therefore no ﬂuorescent signals are produced (no green, blue or orange clusters). A secondary cluster above the gray double-negative cluster
was observed for HG00594 (B) and NA19663 (C) which is likely due to residual signal originating from the rs16947T-labeled binding to the rs16947C allele. This
phenomenon is absent in the homozygous variant sample NA20360, which lacks rs16947C.

does not interfere with cluster analysis. Interference by the
CYP2D7 gene is unlikely since no other cluster(s) were present
in NA19663 (or other samples with the same genotype) (Figures
2B, C).
Taken together, we demonstrated that the custom TaqMan®
assay reaction set-up can determine SNP linkage over a distance
of 116 kb.

efﬁciency when both are present in the same droplet. As
described by Whale et al., this does not interfere with cluster
interpretation as long as the double-positive cluster is distinct
and identiﬁed by the QuantaSoft software (Whale et al., 2016).
When both loci are heterozygous (illustrated for HG00594 in
Figure 2B), three positive ﬂuorophore clusters were observed.
Note that the reference alleles in this assay are not visualized on
the scatter plot as they are targeted by “dark” probes. However,
when both the reference and variant alleles are present in a
droplet, ﬂuorescent hydrolysis endpoint may not be achieved
because of competition for the reaction components. As a result,
there are droplets generating varying ﬂuorescent intensities
which presented as “rain” on the scatter plot (Regan et al.,
2015). For HG00594 we also observed a low amplitude gray
FAM sub-cluster, near the no-ﬂuorophore cluster. NA19663
(homozygous reference for rs16947 and rs5758550) also
presented with this low amplitude sub-cluster (Figure 2C).
The presence of this cluster in both the homozygous reference
and the compound heterozygous control samples and not in the
homozygous variant control, is likely caused by unspeciﬁc
binding of the rs16947varT probe to the rs16947 “C” allele.
The signal of this sub-cluster is automatically combined with the
no-ﬂuorophore cluster by the QuantaSoft software and therefore
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DropPhase Mile Marker
A “mile marker” experiment was utilized to establish linkage
between rs16947 within the CYP2D6 gene and selected SNPs at
distances of 25 kb (rs28817600 “G”), 75 kb (rs5758562 “C”), and
the “enhancer” SNP at over 116 kb (rs5758550 “G”) (Table 1,
Figure 3). As expected, with increased distances between the
interrogated SNPs, decreased percentages of linked molecules
were observed, which we attributed to DNA integrity. This
experimental set-up allowed us to evaluate the suitability of
DNA preparations for long-distance phasing.
To avoid “artiﬁcial linkage” signals that may be caused by
uneven distribution of DNA during droplet generation, two
different negative control reactions were performed (Figure 3):
1) HMW DNA was subjected to the restriction enzyme EcoRI,
that cuts DNA between the SNPs of interest, and 2) the FAM-
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rs16947
C>T
T FAM
C FAM

25 kb
rs28817600
A>G
G

enhancer
116 kb
rs5758550
A>G

75 kb
rs5758562
G>C
C

VIC

G

VIC

VIC

CYP2D6
sample
ID
HG00275
NA20360
HG00594
NA12248
HG00650
NA19663

CYP2D6
genotype
*2/*2
*2/*2
*1/*2
*1/*35
*10/*10
*1/*1

enhancer rs16947
genotype genotype
T/T
G/G
T/T
G/G
C/T
A/G
C/T
A/G
C/C
A/A
C/C
A/A

%
linkage to
rs16947
T
29.8
18.7
15.4
15.7
n/c
n/c

%
linkage to
rs16947
T
55.0
65.5
60.9
58.1
n/c
n/c

%
linkage to rs16947
after EcoRI digest

T
15.3
14.7
10.2
8.6
n/c
n/c

C
n/c
n/c
1.1
0.0
n/c
n/c

T
0.1
0.3
0.1
0.3
n/c
n/c

FIGURE 3 | Mile Post experiment to establish single-nucleotide polymorphism (SNP) linkage. SNPs at increased distances relative to the CYP2D6*2 core SNP
(rs16947) were interrogated to establish DropPhase2D6. The percent (%) linkage between SNPs is decreasing as the distance between interrogated SNPs
increases. SNPs that are trans-conﬁgured show no/little linkage (e.g., rs16947A and rs5758550G). No linkage was observed when DNA was pre-treated with the
restriction enzyme EcoRI. n/c, negative control, i.e., genotype does not support signal generation with respective probe/assay combinations.

labeled assay for rs16947 “C” (reference) was paired with the
VIC-labeled assay for rs5758550 “G” (variant). This duplex
reaction served as a negative control, while the rs16947varT
+rs5758550varG duplex reaction detected linkage for sample
HG00594. Furthermore, no linkage signal is observed for the
rs16947varT+rs5758550varG duplex reaction when the DNA
was pretreated with EcoRI. Thus, the combined results of these
two duplex assays corroborate that rs16947 “T” and rs5758550
“G” are cis-conﬁgured, while rs16947 “C” and rs5758550 “G” are
trans-conﬁgured (Figure 3).

therefore evaluated different methods to obtain HMW DNA
from blood and liver tissue samples (Table 3). DNA isolated
from whole blood or white blood cells with the PrepFiler
Forensic DNA Extraction kit supported linking SNPs at
distances of 25 kb and 116 kb, but were not completely
abolished when the DNA was pretreated with EcoRI (to serve
as a negative control) (Table 3). In addition, we were unable to
extract DNA of sufﬁcient integrity from frozen liver tissue
(assessed by gel electrophoresis) to perform DropPhase2D6
(not shown).
The linkage results for DNA extracted with the Qiagen
MagAttract kit were comparable to those described for the
PrepFiler Forensic Kit. The integrity of DNA extracted from
liver tissue was also not sufﬁcient. In contrast to the PrepFiler
Forensic Kit, EcoRI-pretreated DNA was digested to completion
and did not yield linkage rates above background (Table 3).

High Molecular Weight DNA Isolation
Methods
Since silica column-based DNA extraction methods, including
the DNeasy Blood and Tissue Kit, did not produce DNA of
sufﬁcient integrity for long range experimental phasing, we

TABLE 3 | DropPhase2D6 using high molecular weight (HMW) DNA prepared with different methods.
DNA Kit

Source

CYP2D6
Genotype

rs16947varT +
rs28817600varG
25 kb

rs16947varT +
rs28817600varG
(+RE) 25 kb

rs16947varT +
rs5758550varG
116 kb

rs16947varT +
rs5758550varG
(+RE) 116 kb

rs16947refC +
rs5758550varG
116 kb

DNeasy
DNeasy
PrepFiler
Forensic
PrepFiler
Forensic
MagAttract
MagAttract
MagAttract
MegaLong
MegaLong
MegaLong

WB
Tissue
WB

*1/*2
*1/*2
*1/*2

15.45
1.8
49.06

0.33
0.14
16.36

0.64
-0.66
4.69

0.34
ND
2.93

0.03
-0.39
0.8

WBC

*1/*2

57.26

18.85

6.85

1.72

0.62

WB
WBC
Tissue
WB
WBC
Tissue

*1/*17
*1/*2
*1/*2
*1/*2
*2/*4
*1/*2

52.84
50.18
25.81
82.84
66.43
63.9

0.64
−1.1
−0.4
3.13
2.49
3.89

3.83
1.44
0.48
40.21
41.72
13.62

0.71
2.47
0.09
−0.01
−2.41
0.73

−0.38
−0.8
0.44
−2.58
−0.02
1.16

DNA was prepared from liver tissue, whole blood (WB), and white blood cells (WBC) using different commercially available DNA extraction kits. All kits produced DNA of sufﬁcient integrity to
perform linkage over a distance of 25 kb. The MegaLong kit was, however, superior for phasing over the longer distance of 116 kb, as demonstrated by high values of percent linkage. For
DNA samples prepared with the PrepFiler Kit, false-positive linkage was observed in the negative controls reactions, i.e., when DNA was pre-treated with restriction enzyme EcoRI (+RE).
This was only observed for this extraction kit and is likely due to incomplete digestion by the enzyme. Samples with at least 5% linked molecules and a difference of at least 5% linked
molecules between positive and negative control duplexes are shown in bold.
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Experimental Phasing With DropPhase2D6

The dialysis-based G-Biosciences MegaLong kit was the only
commercial kit that yielded the long fragments of DNA
necessary for DropPhase2D6 from whole blood, white blood
cells, and liver tissue. The DNA prepared with this kit could also
be readily cut with the EcoRI restriction enzyme resulting in
minimum residual linkage. Also, DNA extracted with the
MegaLong kit produced the overall highest linkage percentages
of all methods evaluated.
Because the G-Biosciences MegaLong Kit yielded superior
HMW DNA preparations across all sample sources and
produced consistent linkage results for SNPs at 25 kb and 116
kb, this kit was employed to prepare all subsequent samples.

A

Sample 1
*1

Dark

C

116 kb

CYP2D6
rs16947C>T
FAM

*2

T

CYP2D6

A

Dark

rs5758550A>G

G

Of the DNA samples available for further study, n=40 samples
were chosen for DropPhase2D6 based on the following criteria:
availability of blood or tissue for HMW DNA preparation,
genotype (heterozygous for rs5758550 and rs16947),
ambiguous phase call and/or was genotyped for a rare allele
e.g., CYP2D6*59 which was not captured by computational
phasing. As detailed in Figure 4, DropPhase2D6 was
performed with the rs16947varT+rs5758550varG and
rs16947refC+rs5758550varG duplex reactions. Figure 4A
displays the result for a sample with a CYP2D6*1/*2 genotype
for which DropPhase2D6 demonstrated that the “enhancer” SNP
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*1/*17

*17

*1/*17

*17

*9/*17

*17

*1/*17

*17

*1/*17

*17

*1/*17

*17

*1/*29

*1

*1/*29

*1

*1/*29

*1

*1/*29

*1

*1/*29

*1

*4/*29

*4

*1/*29

*1

*1/*41

*41

*1/*41

*41

*1/*41

*1

*1/*45 (*46)

*45

*1/*45 (*46)
*1/*35

*1
*35

*1/*35

*35

*1/*59

*59

*4/*59

*59

*1/*5

*1

*1/*5

(*5)

*3/*5

(*5)

*5/*17

*17

*5/*29

(*5)

FIGURE 4 | DropPhase2D6 summary and data. The ﬁgure provides DropPhase2D6 results for selected samples, sample types and duplex reactions used to
experimentally link the “enhancer” single-nucleotide polymorphism (SNP) with CYP2D6 haplotype. Phase-predicted genotypes were compiled from datasets_all (all
ethnicities phased together). (A) Sample 1 was genotyped as CYP2D6*1/*2.001. The “enhancer” SNP was conﬁrmed to be cis-conﬁgured, i.e., located on the
*2.001 allele. The rs16947varT+rs5758550varG and rs16947refC+rs5758550varG duplex reactions were utilized to establish linkage. (B) Sample 36 was genotyped
as CYP2D6*1/*5. The “enhancer” SNP was conﬁrmed to be cis-conﬁgured, i.e., located on the *1 allele as predicted by computational phasing. The rs16947refC
+rs5758550varG and rs16947refC+rs5758550refA duplex reactions were utilized to establish linkage for this case. (C) Sample 39 was genotyped as CYP2D6*5/*17.
The duplex reactions rs16947varT+rs5758550varG and rs16947varT+rs5758550refA were used to establish linkage. The “enhancer” SNP was conﬁrmed to be cisconﬁgured, i.e., located on the CYP2D6*17 allele as predicted by computational phasing. The middle panel visualizes DNA molecules sequestered in droplets with
colors representing SNPs generating VIC (green) or FAM (blue) signals. The right-hand table provides sample source (liver tissue; WB, whole blood; WBC, white
blood cells), genotype and ethnicity (C), Caucasian/European ancestry, AA (African ancestry) Unk (unknown), and AA+C (mixed ancestry). The far-right column
indicates to which allele the “enhancer” SNP was experimentally linked. DropPhase2D6 results for samples 11, 25 and 35 were conﬁrmed with the assay for the
CYP2D6*4 core SNP. Speciﬁcally, the reference allele of the “enhancer” SNP was linked with 1847G (rs3892097. reference G) for samples 11 and 35, while linkage
between the “enhancer” SNP and 1847A (rs3892097, variant A) was conﬁrmed for sample 25.
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is located on the *2 allele. Figure 4B provides an example of a
sample with a CYP2D6*1/*5 genotype. In this case,
DropPhase2D6 was performed with the rs16947refC
+rs5758550varG and rs16947refC+rs5758550refA duplex
reactions which revealed that the “enhancer” SNP is in cis with
the CYP2D6*1 haplotype. Figure 4C provides the result for a
sample genotyped as CYP2D6*5/*17 tested with the rs16947varT
+rs5758550varG and rs16947varT+rs5758550refA duplex
reactions. In this example, the “enhancer” SNP was linked with
rs16947, which is part of the CYP2D6*17 haplotype (Figure 1).
The table in Figure 4 provides the results, along other pertinent
information for the 40 samples selected for experimental
validation by DropPhase2D6. The presence of the “enhancer”
SNP was conﬁrmed for the majority of CYP2D6*2 alleles, but
also demonstrated that the “enhancer” SNP can be located on
other haplotypes including CYP2D6*1, *4, *5, *17, *35, *41, *45,
and *59. We did not ﬁnd the “enhancer” SNP on any CYP2D6*3,
*9, or *29 alleles. HMW DNA was not available for the two
samples for which PHASE predicted the “enhancer” SNP to be
on the CYP2D6*10 allele. For the sample genotyped as
CYP2D6*4/*29 and predicted by PHASE to have the
“enhancer” SNP on the *29 allele, DropPhase2D6 revealed that
rs16947T, which is part of the*29 haplotype, is in trans with the
“enhancer” SNP indicating that it is on the *4 allele. The location
of the “enhancer” SNP on the CYP2D6*4 allele was conﬁrmed by
ﬁnding 1847A in cis with the “enhancer” SNP (Figure 4). The
1847G>A assay allows to experimentally phase the “enhancer”
SNPs for samples with genotypes such as CYP2D6*1/*4.
Eleven Coriell DNA samples for which 10X Linked-Reads
were available were chosen for experimental conﬁrmation by
DropPhase2D6. Unfortunately, only sample HG00589 was of
sufﬁcient integrity to determine linkage (i.e., linkage was >5%)
(Table 4). An additional ﬁve Coriell samples were tested with
DropPhase2D6; these were previously predicted by Ray et al.

TABLE 5 | Examination of selected Coriell samples predicted by Ray et al.
(2019) to contain novel CYP2D6 haplotypes.
Sample
ID

Genotype

HG00190

*1/*2

HG01067

*2/*4

NA19672

*1/*68+*2

NA19338

*2/*5

HG00651

*5/*36+*10

Haplotype ID and SNPs
Allele linked
present/absent per Ray et al.,
to
2019 (ref)
“enhancer”
SNP
H1c rs5758550, no rs16947,
rs5758550, rs35742686
(*3)
H1b rs5758550, no rs16947,
rs5758550, rs3892097
(*4), rs1065852 (*10)
H2c rs5758550, rs16947,
rs1065852 (*10)
H3d rs16947, no rs5758550,
rs5030656 (*9)
H1d rs5758550, no rs16947,
rs1065852 (*10)

*2

*2

*2
*2
*5

Extensive genotyping was performed on these Coriell DNA sample to conﬁrm/refute the
haplotypes predicted by Ray et al. (2019). Our genotyping and DropPhased2D6 results do
not conﬁrm the predicted novel haplotypes.

(2019) to either harbor novel CYP2D6 haplotypes or have unique
haplotypes regarding the “enhancer” SNP (Coriell IDs were
kindly provided by Danxin Wang) (Table 5). All ﬁve samples
met the 5% threshold and therefore allowed us to successfully
determine the phase of the “enhancer” SNP. The haplotypes
provided by Ray et al. were found to be inconsistent with our
genotyping results and thus, the “enhancer” SNP was not
detected on a rare allele as predicted (Table 5). For example,
HG00190 was genotyped as CYP2D6*1/*2 and the “enhancer”
SNP linked with the *2 allele which contrasts the “*3 with
“enhancer” SNP” prediction by Ray et al. (2019). Another
example is NA19338 for which Ray et al. predicted that “*2
and *9 SNPs are on the same allele”. However, this sample was
genotyped as CYP2D6*2/*5 with DropPhase2D6 linking the
“enhancer” SNP to the *5 allele.

TABLE 4 | 10X Genomics Linked-Reads technology to phase enhancer singlenucleotide polymorphism (SNP).

DropPhase2D6 Validation With 10X
Linked-Reads

Sample ID

Genotype

HG00436
HG00589
NA12003
NA12813
NA18552
NA18959
NA18973
NA18980
NA19207
NA19239
NA19819

*2x2/*71
*1/*21
*2/*3
*2/*4
*1/*14
*2/*36+*10
*1/*21
*2/*36+*10
*2/*10
*15/*17
*2/*4x2

The phase of the “enhancer” SNP was determined with 10X
Genomics Linked-Reads for 11 Coriell samples (Table 4).
DropPhase2D6 was successfully performed on one Coriell
sample (HG00589) conﬁrming the location of the “enhancer”
SNP on the CYP2D6*21 (Supplemental Figure 1). 10X
technology also revealed that the “enhancer” SNP is on
CYP2D6*14, and not the *1 allele of sample NA18552.

Allele predicted to
Allele to which the
carry the
“enhancer” SNP is
“enhancer” SNP linked by 10X Linkedper PHASE
Reads
N/A1
N/A1
*2
*2
N/A1
*2
N/A1
*2
*2
N/A1
*2

*2
*212
*2
*2
*14
*2
*21
*2
*2
*17
*2

DISCUSSION
In this investigation, we have successfully assigned the “enhancer
SNP” to CYP2D6 star alleles in a data set of >3000 subjects using
computational phasing, determined population-speciﬁc
differences regarding the prevalence of star alleles with and
without the “enhancer” SNP, experimentally validated
predicted haplotypes using DropPhase2D6 and explored
alternative methods for long-distance phasing.

DNA samples investigated for linkage between rs16947 and rs5758550 using 10X
Genomics Linked-Reads. Only one sample, HG00589, was of sufﬁcient integrity to
support DropPhase2D6 (visualization see Supplemental Figure 1). 1 Samples
contained rare CYP2D6 alleles which were identiﬁed via Sanger sequencing; the SNP
identifying the rare alleles were not part of the PHASE analysis. 2DropPhase2D6 conﬁrmed
linkage on the CYP2D6*21 allele.
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allele (Figure 4). DropPhase2D6, however, experimentally linked
the “enhancer” SNP to their *1 allele. One also needs to bear in
mind that CYP2D6*1 is a default assignment and therefore
comprises alleles with SNPs that were not included in our
phasing dataset (e.g., *15, *22, *27, *33, *39, *43, and many
other alleles) because these alleles are not routinely genotyped (a
small number of samples known to having one of these rare
alleles were excluded from the PHASE dataset). Thus, the
number of true *1 alleles carrying the “enhancer” SNP is likely
lower. Similarly, CYP2D6*11, *12, *19, *21, *59, and numerous
other haplotypes were defaulted to a CYP2D6*2 assignment
which likely contributes to an over-estimation of true *2 alleles
carrying the “enhancer” SNP. A limited number of samples have
been genotyped for additional variants revealing, among others,
two samples heterozygous for the CYP2D6*59 allele (CYP2D6*1/
*59 and *4/*59). DropPhase2D6 unequivocally linked the
“enhancer” SNP with the CYP2D6*59 allele. Another two
samples for which HMW DNA was available were genotyped
as CYP2D6*1/*45; one had the “enhancer” SNP on the *45 allele
while the other had it on the *1 allele (Figure 4).
Our computational phasing data suggests that the “enhancer”
SNP may not, or only in rare cases, be present on certain
haplotypes (e.g., CYP2D6*3, *4, *6, *9, *10, *29, and *45) or
almost always be present on others (e.g., CYP2D6*35). However,
these are predictions and should be viewed with caution. A case
in point is CYP2D6*4. We experimentally conﬁrmed the
“enhancer” SNP on the CYP2D6*4 allele in one sample;
however, this was not the subject predicted by PHASE.
Although CYP2D6*4 alleles with the “enhancer” SNP appear to
be rare, their frequency may be under-estimated. Thus, it is
important to realize that computational phasing, while being a
powerful tool, does not necessarily accurately predict on which
allele the “enhancer” SNP is located.

Computational Phasing
Computational phasing can be utilized to infer CYP2D6“enhancer” haplotypes present in a population and their
frequencies (Table 2). Although algorithms, such as PHASE,
are powerful statistical tools, results warrant critical evaluation,
and ideally, experimental validation. This is especially true for
haplotypes that occur at low frequencies as samples homozygous
for low frequency events may not be present in the sample set
available for analysis. Furthermore, PHASE predictions may be
impacted by the differing frequencies of allelic variants among
populations (Gaedigk et al., 2017). These limitations are
exempliﬁed by CYP2D6*29. When samples of the multi-ethnic
dataset (dataset_all) were phased together, 16 of the 129
CYP2D6*29 alleles were predicted to have the “enhancer” SNP.
In contrast, when phasing was performed using separate
datasets, the European (dataset_E) and African ancestry
(dataset_A), PHASE analysis predicted only one CYP2D6*29
allele to carry the “enhancer” SNP. We attribute the observed
differences in the phasing results to population-speciﬁc
haplotype structures. As shown in Figure 4, the absence of the
“enhancer” SNP on CYP2D6*29 was experimentally conﬁrmed
by DropPhase2D6 in eight samples genotyped as compound
heterozygotes for the *29 and “enhancer” SNPs (HMW DNA
was not available for the other eight samples). Of particular
interest is that DropPhase2D6 linked the “enhancer” SNP to the
CYP2D6*4 allele of a *4/*29 sample, while PHASE predicted it to
be on the *29 allele. This was unexpected, since only one of the
971 CYP2D6*4 alleles was predicted to have the “enhancer” SNP.
The CYP2D6*4 allele was sequenced and found to match the
*4.004 suballele deﬁnition. It remains to be seen, however,
whether this suballele always carries the “enhancer” SNP.
Phasing also revealed that the SNPs at positions −1584C>G
(rs1080985), 2851C>T (rs16947), and the “enhancer” SNP
(rs5758550) are highly linked in some populations, but not
others. Therefore, one cannot necessarily assume that each
CYP2D6*2 allele carries −1584C>G and the “enhancer” SNP.
Also, worth highlighting is that the converse appears to be true
for CYP2D6*41, i.e., the vast majority are predicted to lack
−1584C>G (rs1080985) and the “enhancer” SNP. Phasing also
revealed that a signiﬁcant number of the CYP2D6*5 gene
deletion alleles among the European and African ancestry
cohorts have the “enhancer” SNP (9.2 and 9.6%, respectively)
and that CYP2D6*1 alleles with the “enhancer” SNP are
predominately found among samples with African ancestry
(29.2% African and 0.7% European; African and European
ancestry samples phased separately, Table 2). As shown in
Figure 4, the “enhancer” SNP was indeed mapped to the
CYP2D6*1 allele for 11 samples of African ancestry, while the
“enhancer” SNP was on the opposite allele for the samples of
European ancestry supporting the computational phasing
results. While powerful, computational phasing predictions
should always be viewed with caution, especially for complex
and highly polymorphic genes such as CYP2D6. This notion is
highlighted by two samples of African and unknown ancestry
(samples 8 and 9, both genotyped as CYP2D6*1/*2), for which
phasing predicted the “enhancer” SNP to be on their CYP2D6*2
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High Molecular Weight DNA Isolation
Methods
HMW DNA is a prerequisite for long-distance phasing. To
support this study we sought to identify a method that
produces DNA of the required integrity from a broad range of
biological samples including whole blood, white blood cells and
tissue (used fresh or frozen). Of the tested commercially available
products, the dialysis-based MegaLong™ DNA Extraction Kit
yielded consistent results in our hands with superior
performance across all positive and negative control reactions.
HMW DNA was subjected to DropPhase2D6 within 2 weeks of
preparation for best linkage results. Although not systematically
evaluated, the integrity of DNA appeared to be compromised
over time, due to repeated handling (pipetting) and freezethaw cycles.
Since existing and previously handled Coriell DNA samples
produced highly variable linkage results or failed altogether,
selected DNA samples were re-purchased and handled as
described for HMW DNA. Despite these precautions, less than
half produced results surpassing the 5% linkage threshold. While
all DNAs were of “high quality” (per gel electrophoresis), their
integrity was not quite sufﬁcient for long-distance linkage
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analysis. These challenges could be overcome, however, with a
new DNA isolation method the Coriell Institute is planning to
offer in the near future.

haplotypes were consistent with our genotype results and
DropPhase data, highlighting the limitations of predicting
CYP2D6 haplotype from 1000 Genomes Project data without
experimental conﬁrmation.
One particular limitation for ddPCR-based long-range linkage
analyses such as DropPhase2D6 is the availability of HMW DNA,
which may prevent re-analysis of samples for which there are no
source materials (blood, cells, or tissue) available to prepare DNA
of sufﬁcient integrity. The fact that the development of
DropPhase2D6 was limited to assays linking rs16947 (present in
CYP2D6*2 alleles and many others) or rs3892097 (present in
CYP2D6*4) with the “enhancer” SNP (rs5758550) could also be
viewed as a limitation. Indeed, linkage could not be established for
samples which are homozygous (reference or variant) for rs16947,
e.g., samples with a CYP2D6*17/*41, *17/*29, or *1/*9 genotype.
However, concordant DropPhase2D6 assay results lends
credibility to the approach. We are currently validating
additional probe sets that will allow us to analyze samples which
have eluded analysis with the probe sets described in this report.
In conclusion, the “enhancer” SNP is not conﬁned to the
CYP2D6*2 allele and a given star allele can occur with and
without the “enhancer” SNP. Additionally, there are substantial
differences among populations in the frequency of alleles with
and without the “enhancer” SNP. Thus it remains to be seen,
whether the inclusion of this SNP will improve phenotype
prediction from genotype data. Furthermore, it has also been
proposed that testing the “enhancer” SNP in lieu of SNPs that
identify particular star alleles is superior over current genotype
approaches. DropPhase2D6 will allow us to map the “enhancer”
SNP to star alleles, which is essential for future studies assessing
the relationship between CYP2D6 genotype and activity.

DropPhase2D6
Experimentally linking SNPs over distances exceeding those that
can be ampliﬁed by long-range PCR (up to approximately 20 kb)
remains a challenge. Although technologies such as 10X
Genomics Linked-Reads (discussed in more detail below) are
establishing themselves as powerful tools, cost is a major barrier
for their use in routine clinical and research applications and the
vendor has recently announced that support for the platform will
end in July, 2020. ddPCR is increasingly utilized for DNA and
RNA quantiﬁcation, detection of tumor-derived DNA and
pathogen detection to name a few (Li et al., 2018; Liao et al.,
2019; Nyaruaba et al., 2019; O'Hara et al., 2019; Oscorbin et al.,
2019; Valpione and Campana, 2019), but can also be employed
for linkage analysis (Roberts et al., 2014; Karlin-Neumann and
Bizouarn, 2018; Lunenburg et al., 2018; Regan and KarlinNeumann, 2018; Tsujimoto et al., 2018). Since assays can easily
be developed by the user and cost-effectively performed,
DropPhase2D6 was established to experimentally determine
linkage between the “enhancer” SNP and known CYP2D6
haplotypes. The typical turnaround time including DNA
isolation is approximately 24 h.
The interpretation of linkage assay results can be challenging
if the majority of DNA molecules do not span the interrogated
distance, i.e., the number of droplets producing both FAM and
VIC signals (orange cluster) does not exceed or barely exceeds
what would be expected by chance. Since there is no standard
procedure, we utilized a conservative cut-off value of 5%
difference between the percent linkage observed and respective
negative controls to call linkage (Table 3). Positive calls may be
made for samples with differences <5%, especially when all four
duplex reactions were performed in triplicate as described by
Regan et al. (2015).
DropPhase2D6 results conﬁrmed computational predicted
“enhancer” SNP linkage for the majority of samples tested
which lends validity to the method and conﬁdence to the
results contradicting phase prediction. To further validate
DropPhase2D6 we utilized 10X Genomics Linked-Read data of
Coriell DNA samples with existing CYP2D6 genotype data.
Although only one of the selected 11 samples was suitable for
DropPhase2D6, both methods produced consistent results and
the 10X results of the remaining 10 samples were concordant
with those predicted by computational phasing (Table 4). Once
HMW DNA will be available from the Coriell Institute,
additional validation will be perform on these samples.
Ray and colleagues have recently published haplotypes
containing different combinations of the “enhancer” SNP
(rs5758550) and rs16947 (Ray et al., 2019). These tentatively
novel haplotypes were inferred from 1000 Genomes data, but
have not been veriﬁed by genotyping or sequencing by the
authors. In order to follow up on those ﬁndings as well as
determine whether the “enhancer” SNP is indeed located on
respective novel haplotypes, ﬁve Coriell DNAs were included in
the current study. As shown in Table 5, none of the predicted
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TABLE S1 | Genotyping methods. To standardize our genotyping method we
utilized a reporting format that was recommended by PharmVar and PharmGKB
(Nofziger et al., 2020). The ﬁrst tab labeled ‘Methods’ provides brief overviews of the
methods used for genotyping. The second tab labeled ‘CYP2D6 SNPs tested’
provides detailed information of sequence variants tested. All SNP positions are in
reference to the CYP2D6 RefSeq NG_008376.3 with the ATG start codon being +1
according to PharmVar at https://www.pharmvar.org. 1 rs133333 is in complete
linkage with rs5758550. Initially, rs133333 and rs5758550 were both reported as
possible “enhancer” SNPs and genotyping was done for rs133333, rs5758550 or
both. Ultimately rs5758550 was characterized as the functional “enhancer” SNP.
2
SNP utilized for computational PHASE analysis. 3 Samples known to have these
SNPs were excluded from the computational PHASE dataset; however, some of
these samples were chosen for the DropPhase2D6 assay if HMW gDNA was
available.
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FIGURE S1 | Visualization of 10X Genomics Linked-Reads. The genotype of
Coriell sample HG00589 was determined by genotyping and Sanger sequencing
and the “enhancer” SNP linked to the CYP2D6*21 allele by DropPhase2D6. 10X
Genomics Linked-Reads analysis corroborated the DropPhase result. As can be
seen in the Loupe screenshots, the “enhancer” SNP is located on the same
chromosome (arrow, upper line representing chromosome 1) as the CYP2D6*21
core allele SNPs rs16947 and rs72549352 (arrows, also on the upper line). The top
panel indicates Chr22 coordinates and the blue graph at the bottom represents the
genes in which the SNPs are located. Additional details can be found at https://
www.10xgenomics.com.
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